AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Ligand Pharmaceuticals Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S8CH99
303.53▼ 4.29 (-1.39%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
307.82
Day's Range
302.37 – 313.28
52-Week Range
175.89 – 326.63
Volume
366.5K
Avg Volume
257.6K
Share Statistics
Shares Outstanding
Employees
47
Exchange
XNAS
Listed
1994-11-25
Share count as of August 4, 2026

Ligand Pharmaceuticals Inc. (LGND) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Ligand Pharmaceuticals Inc. (LGND)
What is Ligand Pharmaceuticals Inc.'s Market Cap?
Ligand Pharmaceuticals Inc.'s Market Cap is $6.1B, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s Enterprise Value?
Ligand Pharmaceuticals Inc.'s Enterprise Value is $5.8B, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s Trailing P/E?
Ligand Pharmaceuticals Inc.'s Trailing P/E is 30.7×, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s Price / Sales?
Ligand Pharmaceuticals Inc.'s Price / Sales is 20.8×, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s EV / Revenue?
Ligand Pharmaceuticals Inc.'s EV / Revenue is 20.0×, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s EV / EBITDA?
Ligand Pharmaceuticals Inc.'s EV / EBITDA is 45.6×, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s Revenue (TTM)?
Ligand Pharmaceuticals Inc.'s Revenue (TTM) is $290.5M, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s Net Income (TTM)?
Ligand Pharmaceuticals Inc.'s Net Income (TTM) is $197.2M, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s EBITDA?
Ligand Pharmaceuticals Inc.'s EBITDA is $127.6M, based on as-reported figures from SEC (XBRL) filings.
What is Ligand Pharmaceuticals Inc.'s Diluted EPS (TTM)?
Ligand Pharmaceuticals Inc.'s Diluted EPS (TTM) is 9.89, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · LGNDAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues and income:
Total revenues and income
YoY growth+33.7%+14.1%+39.4%+122.8%
Operating costs and expenses:
Cost of Captisol
Amortization of intangibles
Research and development
General and administrative
Fair value adjustments to partner program derivatives
Total operating costs and expenses
Operating income (loss)
% of revenue13.5%33.6%23.2%47.6%
Non-operating income and expenses:
Gain (loss) from short-term investments
Gain (loss) from change in fair value of equity-method investments and other investments
Interest income
Interest expense
Other non-operating expense, net
Total non-operating income (expenses), net
Income (loss) before income taxes
Income tax (expense) benefit
Net income (loss)
% of revenue76.2%-25.8%75.1%101.6%
Basic net income (loss) per share (in USD per share)
Diluted net income (loss) per share (in USD per share)